US2017360798A1PendingUtilityA1

Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection

58
Assignee: ANAVEX LIFE SCIENCES CORPPriority: Mar 28, 2013Filed: Sep 5, 2017Published: Dec 21, 2017
Est. expiryMar 28, 2033(~6.7 yrs left)· nominal 20-yr term from priority
Inventors:Alexandre VamvakidesTangui Maurice
A61K 31/27A61K 31/341A61K 31/495A61K 31/34A61K 45/06C07D 307/14A61K 31/445A61K 31/55A61K 31/13A61K 31/44A61K 31/435
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention concerns a dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine and method of use.

Claims

exact text as granted — not AI-modified
1 . A dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine. 
     
     
         2 . The dosage form of  claim 1  wherein said neuroprotective amount of A2-72 is from about 0.5 to about 20 mg. 
     
     
         3 . The dosage form of  claim 1  wherein said at least one cooperating acetylcholinesterase inhibitor is donepezil. 
     
     
         4 . The dosage form of  claim 3  wherein the neuroprotective amount of donepezil is from about 0.5 mg to about 23 mg. 
     
     
         5 . The dosage form of  claim 4  wherein the neuroprotective amount of donepezil is from about 0.5 mg to less than about 5 mg. 
     
     
         6 . The dosage form of  claim 5  wherein the neuroprotective amount of donepezil is from about 1 to about 3.5 mg. 
     
     
         7 . The dosage form of  claim 1  wherein said at least one cooperating acetylcholinesterase inhibitor is galantamine. 
     
     
         8 . The dosage form of  claim 7  wherein the neuroprotective amount of galantamine is from about 0.5 mg to about 20 mg. 
     
     
         9 . The dosage form of  claim 1  wherein said at least one cooperating acetylcholinesterase inhibitor is galantamine. 
     
     
         10 . The dosage form of  claim 9  wherein the neuroprotective amount of galantamine is from about 0.5 mg to about 20 mg. 
     
     
         11 . The dosage form of  claim 1  wherein said at least one cooperating acetylcholinesterase inhibitor is rivastagmine. 
     
     
         12 . The dosage form of  claim 11  wherein the neuroprotective amount of rivastagmine is from about 0.5 mg to about 20 mg. 
     
     
         13 . The dosage form of  claim 1  wherein said at least one cooperating acetylcholinesterase inhibitor is memantine. 
     
     
         14 . The dosage form of  claim 13  wherein the neuroprotective amount of memantine is from about 0.5 mg to about 30 mg. 
     
     
         15 . A therapeutic method of neuroprotection in a subject with actual or anticipated neuronal injury comprising administering a neuroprotective dose of A2-73 in conjunction with at least one neuroprotective dose selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine. 
     
     
         16 . The method of  claim 15  wherein said neuroprotective amount of A2-72 is from about 0.5 to about 20 mg. 
     
     
         17 . The method of  claim 15  wherein said at least one cooperating acetylcholinesterase inhibitor is donepezil. 
     
     
         18 . The method of  claim 17  wherein the neuroprotective amount of donepezil is from about 0.5 mg to about 23 mg. 
     
     
         19 . The method of  claim 18  wherein the neuroprotective amount of donepezil is from about 0.5 mg to less than about 5 mg. 
     
     
         20 . The method of  claim 19  wherein the neuroprotective amount of donepezil is from about 1 to about 3.5 mg. 
     
     
         21 . The method of  claim 15  wherein said at least one cooperating acetylcholinesterase inhibitor is galantamine. 
     
     
         22 . The method of  claim 21  wherein the neuroprotective amount of galantamine is from about 0.5 mg to about 20 mg. 
     
     
         23 . The method of  claim 15  wherein said at least one cooperating acetylcholinesterase inhibitor is rivastagmine. 
     
     
         24 . The method of  claim 23  wherein the neuroprotective amount of rivastagmine is from about 0.5 mg to about 20 mg. 
     
     
         25 . The method of  claim 15  wherein said at least one cooperating acetylcholinesterase inhibitor is metamine.

Join the waitlist — get patent alerts

Track US2017360798A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.